

VICPLAS INTERNATIONAL LTD
(Incorporated in the Republic of Singapore)
(Registration No. 199805362R)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE SGX-ST LISTING MANUAL

Pursuant to Rule 706A of the Listing Manual of Singapore Exchange Securities Trading Limited, Vicplas International Ltd. (the “**Company**” together with its subsidiaries, the “**Group**”) wishes to announce the following transaction that occurred during the second half of the financial year ended 31 July 2023:

INCORPORATION OF A WHOLLY OWNED SUBSIDIARY

The Company has incorporated a wholly-owned subsidiary in Singapore (**Subsidiary**) on 13 February 2023. Details of the Subsidiary are as follows:

Name of Subsidiary : FOREFRONT MEDICAL AMERICAS PTE. LTD. (**FMA**)
Issued and Paid-Up Capital : USD\$2.00 comprising of 2 ordinary shares
Principal activities : Manufacturing and selling of medical devices

The incorporation of FMA is funded by internal resources and did not have any material impact on the Group’s earnings per share and net tangible asset per share for the financial year ended 31 July 2023.

None of the Directors or substantial shareholders of the Company has any interest, direct or indirect, in the incorporation of the FMA, save for their shareholdings in the Company.

BY ORDER OF THE BOARD

Walter Tarca
Group Chief Executive Officer
28 September 2023